Randomized adjuvant therapy trial in high-risk lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type I. - Jänicke,F.; Prechtl,A.; Thomssen,C.; Harbeck,N.; Meisner,C.; Untch,M.; Sweep,C.G.; Selbmann,H.K.; Graeff,H.; Schmitt,M. (J Natl Cancer Inst, 2001)